MedTrace Logo

A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization

NCT01797133 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 984

Last updated 2016-02-22

No results posted yet for this study

Summary

We will conduct a cluster randomized controlled trial to compare two antibiotic pre-authorization strategies (Fellow-based vs. Pharmacist-based). We believe that amount and duration of antibiotic consumption would be lower in the pharmacist group while the clinical outcome would be equivalent between two groups.

Conditions

  • All Hospitalzied Patients
  • No Specific Conditions Requires

Interventions

PROCEDURE

ID fellow-based antibiotic pre-authorization

All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.

PROCEDURE

Pharmacist-based antibiotic pre-authorization

All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.

Sponsors & Collaborators

  • Mahidol University

    collaborator OTHER

  • Siriraj Hospital

    lead OTHER

Principal Investigators

  • Pinyo Rattanaumpawan, MD, MSCE · Mahidol University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797133 on ClinicalTrials.gov